VP2-less AAV Vectors for Scalable Gene Therapy Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for large-scale production of adeno-associated virus (AAV) vectors face challenges such as limited scalability, instability, and reduced infectivity, particularly in insect cell systems, which hinder their therapeutic application for diseases like hemophilia A and cystic fibrosis due to the small capsid size and incomplete understanding of capsid protein roles.
Innovation Solution
Development of recombinant AAV vectors lacking the VP2 capsid protein (VP2-less) produced in insect cells, which express VP1 and VP3 proteins, enhancing payload capacity and maintaining infectivity, allowing for efficient commercial-scale production suitable for therapeutic use.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional mammalian production systems are used to produce AAV particles, then the production process is well-established, but the scalability to large-scale production is limited and the manufacturing process becomes cumbersome
Solution Approach 1:
The patent extracts the AAV production process from mammalian cells and transfers it to insect cells, specifically using the baculovirus-insect cell system. This extraction allows the production to be scaled up without the limitations of mammalian cell culture, achieving large-scale production while maintaining process simplicity through the robustness of the insect cell system
Solution Approach 2:
The patent changes the host cell parameter from mammalian cells to insect cells, which fundamentally alters the production capabilities. Insect cells allow for much larger scale production and can be cultured in conditions that are more suitable for industrial-scale manufacturing, thereby resolving the scalability issue
2Quantity of substance
If AAV production is scaled up in mammalian cells to meet clinical requirements, then the particle number increases, but the labor requirements and manufacturing burden increase significantly
Solution Approach 1:
The patent uses baculovirus as an intermediary vector to deliver AAV genes into insect cells. This intermediary system enables efficient gene transfer and expression in insect cells, allowing large-scale production of AAV particles without the manual labor-intensive processes required in mammalian cell systems
Solution Approach 2:
The patent employs the baculovirus system, which is a well-established and highly efficient copying mechanism for gene delivery and expression. By utilizing this proven system in insect cells, the patent achieves high-yield AAV production that is much easier to manufacture at scale compared to mammalian cell systems
3Productivity
If AAV is produced in insect cells, then the scalability improves, but the stability of the viral vectors decreases and sustained production over multiple passages becomes difficult
Solution Approach 1:
The patent performs preliminary optimization of the baculovirus-AAV system before large-scale production. By establishing stable transfection protocols and optimized culture conditions in advance, the patent ensures that the viral vectors maintain their stability and production capability throughout multiple culture passages, enabling both scalability and sustained production
4Productivity
If the capsid size of AAV is reduced to improve packaging efficiency, then the production efficiency increases, but the payload capacity decreases and inability to carry large genes
Solution Approach 1:
The patent changes the host cell parameter from mammalian cells to insect cells, which fundamentally alters the production capabilities. Insect cells allow for much larger scale production and can be cultured in conditions that are more suitable for industrial-scale manufacturing, thereby resolving the scalability issue
Data Source
AI summary
The present invention relates to production of parvoviral vectors to produce adeno-associated virus (AAV) for gene therapy. In particular the invention relates to improvements in parvoviral vectors that increase the packaging capacity, production efficiency, and infectivity of AAV virions that is necessary for large scale manufacturing of AAV for clinical purposes.